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and most of them (76.0%) were active workers. Daily mean
cigarette consumption during working days was 20.7  9.9.
Mean annual expenses for cigarettes reached €961.5  442.3
and the median expense was €876, although signiﬁcant differ-
ences (p < 0.0001) within gender, age groups, educational level,
work situation and geographic area were observed. Men older
than 46–65 years showed the highest expense, regardless of their
income; and unemployed workers spent more than active
workers on tobacco. A mean annual expense for cigarettes higher
than 1500 € was associated with a higher use of smoking cessa-
tion treatments (p = 0.0009). However, less than 0.9% of
smokers wanted to stop smoking due to economic reasons.
CONCLUSIONS: Smokers who want to quit smoking spend
annually a mean of €961.5 (median of €876) on cigarettes,
although there are signiﬁcant differences within socio-
demographic proﬁles. The higher the expenses for cigarettes are,
the higher the expenses for smoking cessation treatments reach.
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OBJECTIVES: Recent regulatory guidelines emphasize the
importance of patient input in the development of patient
reported outcome (PRO) measures that will be used as clinical
trial endpoints to support labelling claims. In asthma prevention
and management, consensus among clinicians is growing regard-
ing models of asthma control. It is uncertain how closely patient
models concur with clinical perspectives of asthma control. The
objective of this research was to develop a conceptual model of
asthma control based on both patient and clinician input and
explore the congruence of patient and clinical perspectives.
METHODS: Fifty-ﬁve patients discussed the concept of asthma
control in 8 focus groups (2 each in France, Germany, UK & US).
Independently two asthma specialists and two general practitio-
ners were interviewed in each country (18 in total) about their
understanding of asthma control, symptoms and treatments.
Data was analyzed using thematic analysis techniques based on
grounded theory, and conceptual models were developed for
patient and clinician perspectives. RESULTS: When asked what
asthma control meant to them, patients talked about symptoms,
sleep disturbance, tiredness, rescue medication use, activity limi-
tations, the experience of asthma attacks and experiencing panic
and fear. Clinicians focussed primarily on presence and severity
of symptoms and medication use, but also mentioned the ability
of the patient to remain active, patients’ hospitalisation, and
satisfaction with and adherence to medication as being indicators
of asthma control. CONCLUSIONS: Our research suggests that
patient and clinician models are complementary, but not com-
pletely consistent. Both emphasize symptom control and rescue
medication use as key indicators. Patients, however, also consider
emotional responses, tiredness and activity limitations as impor-
tant, whereas clinicians more often considered adherence and
health care utilisation. Differences in the models support the
importance of including both patient and clinical perspectives
when developing PRO measures for clinical trials.
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OBJECTIVES: The perceptions of patients and physicians re-
garding the symptoms and impact of allergic rhinitis (AR) were
assessed in a prospective, international, cross-sectional survey
using a convenience sample of consulting patients. We present the
combined survey results from Germany, France, Italy, Spain and
UK. METHODS: Data were recorded by 1482 patients and
matched with records completed by primary care physicians
and specialists. Diagnostic tests to conﬁrm AR had been per-
formed on 1279 (86.3%) patients. Both physicians and patients
recorded the presence, severity and impact of symptoms. Health-
related quality of life (HRQoL) was assessed. RESULTS: A large
proportion of patients had moderate–severe disease (67.2%;
n = 996), persistent disease (42.5%; n = 630) and co-morbidities
such as asthma (31.5%; n = 467). Patients generally rated their
disease as more severe than did their physicians (P < 0.001). At
the time of the consultation, one-third of all patients reported
that their current nasal and ocular symptoms were moderate or
severe in nature. According to the physicians’ assessment, good
control of nasal and ocular symptoms was achieved in 45.4%
(n = 673) and 51.3% (n = 760) of patients, respectively. Overall,
43.3% (n = 641) of those surveyed were using two or more
medicines for their AR. HRQoL was correlated with disease
severity and with the number of days without symptoms in the
previous 4 weeks. AR had a signiﬁcantly greater impact in
patients with more persistent disease than in those with intermit-
tent disease (2.3  1.3 vs. 1.9  1.2; P < 0.001). Nonetheless,
81.8% (n = 601) of patients with intermittent disease reported
some impairment of their daily life as a result of their AR.
CONCLUSIONS: AR remains a signiﬁcant health problem
because of the high burden of symptoms and its impact on
general well being and HRQoL.
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OBJECTIVES: Shortness of breath, chest tightness, wheeze and
cough are hallmark symptoms of asthma. These can signiﬁcantly
impact a patient’s life causing impairment to a patient’s physical,
emotional and social wellbeing. To evaluate a treatment’s efﬁ-
cacy, it is important to assess endpoints that are important to
patients. This study aimed to conﬁrm symptoms and their impact
which are important to asthma patients. METHODS: Fifteen
patients with asthma, meeting predeﬁned inclusion criteria were
recruited by MAPI Values in Boston, USA. All patients con-
sented. The semi-structured interviews explored symptoms and
impact of symptoms. Patients also completed the Asthma
Control TestTM (ACT) and the Asthma Quality of Life Question-
naire (AQLQ(S)). Taped interviews were transcribed maintaining
anonyminity and analysed to answer the key questions in the
interview guide. Findings of the ﬁrst 11 (75%) interviews were
compared with the ﬁnal 4 (25%) interviews to determine the
level of consistency in the pattern of responses. RESULTS: All
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symptoms were recognised by patients using similar language
as symptom descriptors. No additional symptoms were offered.
Frequency, severity and predictability of symptom occurrence
were considered to be relevant features of symptoms. Shortness
of breath was reported to be the main symptom to have an
impact on patients’ lives. Severity and frequency of symptoms
affected the level of impact on a patient’s life. Patients reported
that the main impact of symptoms is the need to use their rescue
medication and limitations on physical activity. Sleep disturbance
and the need to adjust their life to avoid factors that they know
trigger asthma worsenings were also reported. CONCLUSIONS:
The four symptoms were conﬁrmed along with consistency of
terminology indicating homogeneity of understanding amongst
the patients. Findings suggest it is relevant to measure frequency
and severity of symptoms. Symptoms impact a patient’s life in a
number of ways.
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OBJECTIVES: Understanding and identifying impaired quality
of life (QoL) is now recognised as an important component of
asthma and COPD management. The aim of the study was to
assess which factors affect patient’s QoL, to examin the relation-
ship between these factors (outcomes) and the QoL data; as well
as to evaluate the possible differences between patients with
and without a signiﬁcant high level of anxiety/ depression.
METHODS: A total of 130 patients (70 asthmatics and 60
COPD) were analysed in the study. Patients were asked to
respond to self administered questionnaires: the St George’s Res-
piratory Questionnaire (SGRQ), the EQ-5D, the Beck depression
scale and a range of questions concerning smoking habits, inhaler
use technique, disease management. Data was analysed by using
Statistical Programme Package for Social Sciences statistical soft-
ware 15.0; linear multiple regression and factor analysis were
conducted. RESULTS: We found at 5% signiﬁcance level notable
correlation between the SGRQ score and EQ-5D -0,648; Beck
score 0,690; FEV1 0,522; age 0.505. We implied a linear multiple
regression model, where the dependent variable was the SGRQ
score and the independent variables were: FEV1 and the Beck
score (R2 = 0.48; P = 0.001) in model 1; and disease severity/
hospitalisation and Beck score (R2 = 0.55; P = 0.005) in model 2.
In the factor analysis the loading of the 9 outcomes (age, sex,
anxiety/depression, smoking status, lung function, disease
severity/hospitalization, inhaler use technique, disease manage-
ment) onto 5 identiﬁable factors suggest that, patients actual
health status is mainly affected by age, sex, the Beck scale
(depression) and smoking. CONCLUSIONS: Our results suggest
that however correlation is moderately strong between QoL and
clinical outcomes, patients QoL impairment is mainly attribut-
able to depression status, inhalation technique and smoking
status. All of these can be improved by adequate, regular patient
education, resulting in optimal asthma and COPD control.
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OBJECTIVES: To compare generic (EQ-5D, SF-12) and disease-
speciﬁc (SGRQ) instruments for measuring the impact of severe
acute exacerbations on quality of life (QoL) in patients with
chronic obstructive pulmonary disease (COPD) treated in hospi-
tal with regard to acceptance, ceiling effects, sensitivity to change
and discrimination between groups with different disease severi-
ties. METHODS: Patients treated for acute exacerbations
of COPD in the Asklepios-Fachkliniken München-Gauting,
Germany, were asked to complete the questionnaire at admission
and again before discharge. Information about patients’ age, sex,
smoking status and disease severity according to GOLD class-
iﬁcation was collected and EQ-5D, SF-12 and SGRQ were
answered as self-administered questionnaires. Utility values were
calculated for the EQ-5D and the SF-12 based on published
utility weights. For the SGRQ, impact, symptom, activity and
total scores were calculated. T-tests were conducted to compare
proportions of missing values and sensitivity to change. The
impact of different GOLD stages on QoL was assessed using
linear mixed models. RESULTS: Preliminary analyses showed
the highest acceptance for the EQ-5D, with the lowest percentage
of missing utility values. No ceiling or ﬂoor effects occurred for
the SF-12, whereas the SGRQ showed ﬂoor effects particularly
for the dimension activity at both time points. Ceiling effects
occurred for the EQ-5D at discharge. Sensitivity to change was
highest for EQ-5D and SGRQ, whereas only minor changes were
observed for the SF-12. However, differences between GOLD
stages after adjusting for age and sex were best captured by the
SF-12. CONCLUSIONS: The main problem of the SF-12 and
the SGRQ is the high proportion of missing values although the
former differentiates best between GOLD stages. The EQ-5D
seems well suited for this patient group, yet ceiling effects pose a
problem with this severe disease.
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OBJECTIVES: Current asthma treatments according to GINA
2007 guidelines have been designed to offer a better asthma
control and thereby optimal patient well-being. This study aims
to demonstrate their impact on a Greek asthmatic population.
METHODS: A total of 747 patients were included in the study.
614 were included in the analysis (261 males / 353 females, mean
age 49/46 years). They were visiting their primary care physician
(52% general practitioners, 48% specialists) for their asthma. All
patients had moderate to severe asthma and were treated with a
LABA/ICS combination, both for maintenance and relief
(budesonide/formoterol via Turbuhaler® according to the
approved dosage), according to current clinical practice for at
least one month prior to their enrollment. They completed a
package of questionnaires; the Asthma Control Questionnaire
(ACQ), the Asthma Quality of Life Questionnaire (AQLQ), and
questions on treatment satisfaction. RESULTS: Eighty-ﬁve per-
cent of the patients perceived their asthma as controlled. Of
these patients, 67% were well controlled or partly controlled
(WCoPC) (ACQ < = 1.5), 33% were uncontrolled/poorly con-
trolled (UNPC) ACQ > 1.5. Almost half of all patients were on
low maintenance doses (1 inhalation bid) and the other half
on high maintenance doses (2 inhalations bid). 55% of patients
on low maintenance doses were WCoPC compared 40% on high
maintenance doses. Patients with WCoPC reported a good
health-related quality of life (average AQLQ = 6.4), which were
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